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Abstract
Idiopathic pulmonary fibrosis (IPF) is a devastating and progressive lung disease. Its aetiology is thought to involve damage
to the epithelium and abnormal repair. Alveolar epithelial cells near areas of remodelling show an increased expression of
proapoptotic molecules. Therefore, we investigated the role of genes involved in cell cycle control in IPF. Genotypes for five
single nucleotide polymorphisms (SNPs) in the tumour protein 53 (TP53) gene and four SNPs in cyclin-dependent kinase
inhibitor 1A (CDKN1A), the gene encoding p21, were determined in 77 IPF patients and 353 controls. In peripheral blood
mononuclear cells (PBMC) from 16 healthy controls mRNA expression of TP53 and CDKN1A was determined. Rs12951053
and rs12602273, in TP53, were significantly associated with survival in IPF patients. Carriers of a minor allele had a 4-year
survival of 22% versus 57% in the non-carrier group (p=0.006). Rs2395655 and rs733590, in CDKN1A, were associated with
an increased risk of developing IPF. In addition, the rs2395655 G allele correlated with progression of the disease as it
increased the risk of a rapid decline in lung function. Functional experiments showed that rs733590 correlated significantly
with CDKN1A mRNA expression levels in healthy controls. This is the first study to show that genetic variations in the cell
cycle genes encoding p53 and p21 are associated with IPF disease development and progression. These findings support
the idea that cell cycle control plays a role in the pathology of IPF. Variations in TP53 and CDKN1A can impair the response to
cell damage and increase the loss of alveolar epithelial cells.
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Introduction
Idiopathic pulmonary fibrosis (IPF) is a severe and relentless
lung disease that is characterized by fatal scarring of the lung
parenchyma and progressive shortness of breath. IPF is a rare
disease with a prevalence of 14 per 100.000 persons [1]. The
annual incidence is estimated to be between 4.6 and 7.4 cases per
100.000 persons and about 5 million people are affected
worldwide [1–3]. Moreover, the incidence continues to rise and
IPF is now an important cause of respiratory mortality [3].
The median survival time is only 2.5 to 3.5 years, but individual
survival can vary from a few months to .10 years [2,4–6].
Progression of the disease is mainly monitored by lung function
testing, and some studies have found that lung function decline is
associated with survival time [7,8]. However, it is unclear what
causes this heterogeneity in survival time and whether it can be
predicted by any other means.
The cause of IPF remains unknown but is thought to involve
damage to the epithelium and abnormal repair. In 0.5–19% of
cases IPF is familial and is most likely caused by a single genetic
mutation [9]. Apart from deleterious alleles, no rare risk variants
have been found for IPF while a common risk variant in the
MUC5B gene has recently been discovered to associate with both
familial and sporadic IPF [10]. Susceptibility to IPF and
progression of the disease is probably influenced by a combination
of genetic variations that drive epithelial injury and abnormal
wound healing processes [11].
It has been suggested that IPF pathology has similarities to
cancer and that it could be a neoproliferative disease [12].
Previous immunohistological examination of IPF lungs has
revealed increased expression of proteins involved in cellular
responses to injury and DNA damage, including p53 and p21 [13].
Tumour protein 53 (p53) is a key regulator of apoptosis. It is
upregulated upon DNA damage and prevents damaged cells from
becoming malignant by inducing growth arrest and cell death
[14,15]. With increasing age, some cells can escape p53-induced
cell death and the continued presence of these dysfunctional cells
can lead to a decrease in tissue regeneration and repair as well as
cancer [16]. Increased levels of p53 in the lungs of IPF patients are
consistent with increased apoptosis [13]. Loss of alveolar epithelial
cells by apoptosis can impair the regenerative capacity of the lung.
P53-induced growth arrest is mediated by increased transcription
of cyclin-dependent kinase inhibitor 1A (CDKN1A), the gene
encoding p21. The p21 protein (also known as Cip1, Sdi1, and
Waf1) regulates cell cycle progression. Induction of this protein
prevents proliferation and allows optimal DNA repair thereby
reducing apoptosis and cancer risk [17].
Genetic variations may play a role in IPF disease susceptibility
and progression and could give important insights into disease
aetiology [11,18].
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MMaterials and Methods
Ethics statement
The Ethical Committee of the St. Antonius Hospital approved
the study protocol and all subjects gave written informed consent.
Subjects
77 IPF patients who visited the Centre for Interstitial Lung
Diseases at the St. Antonius Hospital, the Netherlands between
November 1998 and 2007 were included in this study.
Diagnoses made before 2002 were reviewed by a clinician and
patients were only included when the diagnosismet the current ATS/
ERS guidelines [ATS/ERS, 2002 565 /id]. Other causes of UIP
(drugs, collagen vascular diseases) were ruled out. 58 males and 19
females (mean age 60.8 years {SD 13.6}) were included. In 58 cases
the diagnosis of UIP was confirmed on lung biopsy (75%). From 64
patients lung functionfollow-up wasavailable. In accordance with the
method proposed by Egan et al. [19], we defined a rapid decline in
lung function as more than 15% decline in percent-predicted DLCO
(diffusion capacity of the lung for carbon monoxide) or more than
10% decline in percent-predicted vital capacity (VC) over a one-year
period. Length of follow-up for survival was up to 4 years and was
based on hospital records. Patients that were still alive or transplanted
were censored in the survival analysis. Clinical parameters at
diagnosis were obtained from hospital records.
The control group consisted of 353 healthy volunteers (mean
age 39.2 years {SD 12.4}, 139 males, 210 females). This included
313 self-reported healthy Caucasian employees of the St Antonius
hospital and 40 volunteers that underwent brochoalveolar lavage
between January and October 2007. The Ethical Committee of
the St. Antonius Hospital approved the study protocol (R-05.08A).
All subjects that met the inclusion criteria and gave written
informed consent were included in this study.
Genotyping
DNA was extracted from whole blood samples and single
nucleotide polymorphism (SNP) typing was conducted using a
custom Illumina goldengate bead SNP assay in accordance with
the manufacturer’s recommendations (Illumina Inc; San Diego,
USA). The tagger program [20] was used to select haplotype
tagging SNPs (tagSNPs) that represent the genetic variation in a
specific region. SNPs were selected using the CEU HapMap panel
and covering the gene region plus 2500 basepairs upstream and
downstream, based on NCBI build 35. We used an r
2 threshold for
SNPs.0.8 under the pairwise tagging options. Three tagSNPs in
the p21 gene, CDKN1A located on chromosome 6p21.2, were
selected based on a minor allele frequency (MAF) higher than 25%
in the Caucasian population and one SNP (rs730506) was added
because of its potential regulatory function on protein expression
through localization on a transcription factor binding site [21]. For
the p53 gene, TP53 located on chromosome 17p13.1, three
tagSNPs were selected by reducing the MAF with 5% increments
until three tagSNPs could be selected with a MAF higher than 5%.
Two potentially functional SNPs were added (rs16956880 and
rs11575997) that could have an effect on splicing [22].
Messenger RNA levels
We used thawed peripheral blood mononuclear cells (PBMC)
from 16 healthy controls. The expression of CDKN1A and TP53
mRNA was analysed by quantitative RT-PCR amplification as
described previously [23]. Briefly, total RNA was isolated using an
Rneasy microkit (Qiagen, Venlo, the Netherlands) according to
the manufacturer’s protocol. 0.2 mg RNA was used for first-strand
cDNA synthesis with the I-script cDNA synthesis kit (Biorad,
Veenendaal, the Netherlands). The obtained cDNA was diluted 1/
10 with water of which 4 ml was used for amplification in a
reaction volume of 20 ml. The PCR was performed with the RT
2
Real-Time
TM SYBR Green PCR master mix (SA-Biosciences,
Frederick, USA) according to the manufacturer’s protocol.
Samples were amplified using a Biorad MyiQ real time PCR
detection system for 40 cycles (10 s at 95uC, 20 s at 61uC and 25 s
at 72uC. The copy number of CDKN1A was normalized by the
housekeeping gene b-actin (ACTB).
Statistics
SPSS 15 (SPSS Inc., Chicago, IL, USA) and Graphpad Prism v.
3 (Graphpad software INC., San Diego, CA, USA) were used for
statistical analysis. The Kaplan-Meier method with log-rank test
was used to analyse whether any SNPs were associated with
survival. Cox regression analysis with covariates was used to check
for possible confounders. Pearson’s goodness-of–fit Chi-square test
and Fisher’s exact test were used to test for deviation from Hardy-
Weinberg equilibrium and for a difference in genotype and allele
frequencies between patients and controls as implemented online
at http://ihg2.helmholtz-muenchen.de/cgi-bin/hw/hwa1.pl. Due
to linkage disequilibrium between the SNPs (figure 1), the effective
Figure 1. Linkage disequilibrium plot. Showing pairwise r
2 for
SNPs in TP53 (A) and CDKN1A (B).
doi:10.1371/journal.pone.0030442.g001
Table 1. TP53 genotype frequency in patients and controls.
TP53 genotype IPF controls
rs12951053 AA 0.88 (68) 0.84 (295)
AC 0.12 (9) 0.16 (56)
CC 0.0 (0) 0.006 (2)
rs12602273 GG 0.86(66) 0.85 (299)
CG 0.14 (11) 0.15 (53)
CC 0.0 (0) 0.003 (1)
rs2287497 GG 0.82 (63) 0.80 (281)
AG 0.18 (14) 0.19 (68)
AA 0.0 (0) 0.01 (4)
rs16956880 GG 1.0 (77) 1.0 (353)
rs11575997 CC 1.0 (77) 1.0 (353)
The values in parentheses are the number of individuals the frequency is based
on.
There were no significant differences between patients and controls.
doi:10.1371/journal.pone.0030442.t001
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proposed by Li and Ji [24] as implemented online at http://gump.
qimr.edu.au/general/daleN/matSpD/.
The adjusted significance threshold was set at 0.05/
4.46=0.011.
Results
TP53
Genotype and allele frequencies for TP53 and CDKN1A SNPs
did not deviate from Hardy-Weinberg equilibrium (table 1).
There were no significant differences in genotype frequency
between patients and controls in TP53 SNPs. There was linkage
disequilibrium between three SNPs (figure 1A): between
rs12951053 and rs12602273 D9=0.85 and r
2=0.68; between
rs12951053 and rs2287497 D9=0.78 and r
2=0.45; and between
rs12602273 and rs2287497 D9=0.98 and r
2=0.68.
Carriership of the minor alleles of rs12951053 (C) or
rs12602273 (G) was significantly associated with shorter survival
time, both individually and when the SNPs are combined
(figure 2A). Carriers of the minor alleles had a 4-year survival of
only 22% versus 57% in the non-carrier group (Kaplan-Meier,
Figure 2. Kaplan-Meier analysis of survival in a cohort of IPF patients. (A) Carriers of the TP53 rs12951053 C or rs12602273 G alleles had
significantly worse 4-year survival rate (p=0.006). (B) There was no significant difference in survival between carriers and non-carriers of the CDKN1A
rs2395655 G allele (p=0.2).
doi:10.1371/journal.pone.0030442.g002
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gender and lung function were no confounding factors. The
hazard ratio for carriership of a TP53 minor allele was 2.9 (95%CI
1.3–6.2, p,0.007). Rs2287497 did not show any association with
survival in our IPF cohort.
The two SNPs in TP53 that were associated with survival were
tested for an association with lung function decline (table 2).
Carriers of the rs12951053 C allele and carriers of the rs12602273
C allele were more likely to have a rapid decline in lung function,
although the difference did not reach statistical significance. In the
rs12951053 AC group 5 of 8 (63%) and in the AA group 15 of 50
patients (30%) had a rapid decline in lung function. Together these
results suggest that carriership of the TP53 rs12951053 C allele or
rs12602273 C allele predisposes to a rapid progression of IPF.
No differences in TP53 mRNA expression were observed
between the p53 genotypes.
CDKN1A
There was significant linkage disequilibrium between the four
CDKN1A SNPs (figure 1B): between rs733590 and rs2395655
D9=0.96 and r
2=0.78;.between rs733590 and rs730506
D9=0.99 and r
2=0.46; between rs733590 and rs3176352
D9=0.62 and r
2=0.23; between rs2395655 and rs730506
D9=1 and r
2=0.40; between rs2395655 and rs3176352
D9=0.76 and r
2=0.30; and between rs730506 and rs3176352
D9=0.81 and r
2=0.50.
All four of the SNPs in CDKN1A were associated with IPF
(table 3). Only the association with rs733590 and rs2395655
remained significant at the adjusted threshold, and the
association was strongest for rs2395655. Carriership of
rs2395655 GG genotype in patients was almost twice as high
as in controls (30% versus 16% respectively, p=0.003). There
is a high degree of linkage disequilibrium within the gene but
haplotype analysis did not generate superior results (data not
shown).
Survival in carriers of rs2395655 G allele was worse than in
non-carriers, however, the difference did not reach statistical
significance (p=0.2, figure 2B). Rs2395655 and rs733590 were
tested for an association with lung function decline (table 2). The
association between rs733590 and lung function decline did not
reach statistical significance. Carriers of rs2395655 G allele were
more likely to have a rapid decline in lung function (p=0.04,
table 2). Nineteen patients (41%) carrying the G allele had a rapid
decline in lung function while only one patient (8%) with the AA
genotype had a rapid decline. This did not remain significant after
correction for multiple testing.
CDKN1A mRNA expression in healthy controls was determined
in relation to beta-actin (ACTB) expression and is shown in
figure 3. CDKN1A mRNA levels were significantly higher in
carriers of the rs733590 T allele, using an uncorrected t-test
(p=0.03 TT+CT vs CC). For carriers of the rs2395655 A allele, a
similar trend was observed (p=0.06).
Table 2. Genotype and lung function decline.
genotype rapid Non-rapid
TP53
rs12951053 AA 15 35
AC 5 3
CC 0 0
rs12602273 GG 16 34
CG 4 4
CC 0 0
CDKN1A
rs733590 TT 3 13
TC 10 17
CC 7 8
rs2395655* AA 1 11
AG 10 18
GG 9 9
Number of IPF patients with non-rapid or rapid decline in %predicted vital
capacity (.10% in one year) or %predicted diffusion capacity (.15% in one
year).
*Fisher’s exact test with carriers of p21 rs2395655G vs. non-carriers resulted in
p=0.04.
doi:10.1371/journal.pone.0030442.t002
Table 3. CDKN1A genotype and carriership frequency in patients and controls.
CDKN1A Genotype IPF controls Carriership IPF controls P value
rs733590* TT 0.31 (24) 0.39 (139) T 0.74 0.86 CC p=0.007
TC 0.43 (33) 0.47 (166) C 0.70 0.61 OR=2.2 (1.23–4.03)
CC 0.26 (20) 0.14 (48)
rs2395655* AA 0.25 (19) 0.34 (120) A 0.70 0.84 GG p=0.003
AG 0.45 (35) 0.50 (177) G 0.76 0.66 OR=2.3 (1.31–4.05)
GG 0.30 (23) 0.16 (55)
rs730506 GG 0.49 (38) 0.59 (208) G 0.89 0.96 CC p=0.013
CG 0.40 (31) 0.37 (132) C 0.51 0.41 OR=3.0 (1.21–7.58)
CC 0.10 (8) 0.04 (13)
rs3176352 CC 0.39 (30) 0.54 (189) C 0.87 0.94 CC p=0.020
CG 0.48 (37) 0.41 (143) G 0.62 0.46 OR=1.8 (1.09–3.00)
GG 0.13 (10) 0.06 (21)
The values in parentheses are the number of individuals. P values are based on the number of individuals with and without the specified genotype and are calculated
using a Pearson’s goodness-of-fit chi-square test. Odds ratio (OR) is shown with the 95% confidence interval in brackets.
*After correction for multiple testing rs733590 and rs2395655 remained significant.
doi:10.1371/journal.pone.0030442.t003
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This study reports the novel finding that SNPs in CDKN1A
predispose to IPF and that SNPs in both TP53 and CDKN1A are
associated with progression in IPF. The SNPs in TP53 had a more
pronounced effect on survival while rs2395655 in CDKN1A had a
more pronounced effect on rapid lung function decline. Survival
was significantly correlated with change in lung function in our
cohort (p=8610
29, results not shown) as is usually observed in
IPF [25]. Together, our findings show that variations in cell cycle
genes are involved in IPF.
Both p53 and p21 are vital cell cycle regulators after DNA
damage and are determining factors in cell fate. Inhaled
substances, like cigarette smoke, can cause DNA damage to lung
cells and exposure to these substances have been associated with
an increased risk of developing IPF [26]. In damaged cells,
upregulation of p53 occurs and this induces growth arrest and
apoptosis. It has been shown that in mice, injury to type II alveolar
epithelial cells caused pulmonary fibrosis [27]. Alveolar type II
cells are progenitors of type I cells and essential for alveolar repair
after induced injury [28]. They react by immediate proliferation
along the alveolar basement membrane. Previous studies have
detected increased levels of proapoptotic molecules in hyperplastic
alveolar epithelial cells in IPF patients [13,29].
However, induction of p21 can rescue a cell from apoptosis
by allowing DNA repair. In addition, p21 has been reported to
be elevated during the differentiation of alveolar epithelial type
II cells into type I cells [30]. We found that the CDKN1A allele
that predisposed to IPF disease development was associated
with decreased CDKN1A mRNA expression. This finding has to
be further investigated in light of previous immunohistochem-
ical findings that showed increased p21 levels in the lungs of
IPF patients [13]. The upregulation of p21 in IPF lungs may
occur later in disease or may be insufficient to prevent disease
progression after injury. Forced expression of the transfected
human of CDKN1A gene in mice resulted in decreased
apoptosis, inflammation and fibrosis after bleomycin installa-
tion [31]. In addition, p21 attenuates epithelial mesenchymal
transition, a process that contributes to the formation of
fibroblast foci [32], and it plays an important role in the
prevention of cancer by inducing cell cycle arrest [33]. This
dual functionality of p21 may therefore explain both the
remodelling in IPF as well as the increased incidence of
carcinomas that is thought to occur in IPF patients [34].
Together this indicates that the absence of p21 causes a pro-
fibrotic environment, while the induced presence of p21 results
in a better healing process.
This study was part of hypothesis generating research and
therefore the findings will have to be validated in an independent
cohort. The SNPs that were associated with IPF in this study are
tagSNPs that represent the genetic variation in the gene region. It
is likely that these SNPs are linked to a functional SNP in another
part of the gene.
The number of patients included in this study was limited, a
problem that almost all studies with IPF patients face. For
instance, an association was found between rs2395655 and lung
function decline (p=0.04). However, due to the correction for
multiple testing, a cohort of at least 80 patients would be needed to
reach the adjusted significance level of p=0.011 with 80% power.
Similarly, at least 46 individuals would be required to reach a
power of 80% for the association between rs2395655 and CDKN1A
mRNA expression. Another limitation of this study is the
difference in age between patients and controls. However, no
effect of age on genotype distribution was observed.
In conclusion, we found that the TP53 rs12951053 and
rs12602273 SNPs were significantly associated with survival in
IPF patients and that CDKN1A SNPs rs2395655 and rs733590
were significantly associated with the risk of developing IPF.
Furthermore, the CDKN1A SNPs were associated with a rapid
decline in lung function and significantly decreased CDKN1A
mRNA levels. This is the first study to show that genetic variation
in the genes encoding p53 and p21 might play an important role in
IPF. Further studies are needed to elucidate the role of cell cycle
genes in IPF pathology.
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